S-1/A: Windtree Therapeutics Files for Resale of Up to 31.2 Million Shares Amid Strategic Shift

Windtree Therapeutics is registering for resale up to 31.2 million shares of common stock by selling stockholders, including shares issuable upon conversion of preferred stock and notes, exercise of warrants, and under an equity line of credit.

Summary

• Windtree Therapeutics has filed a registration statement for the resale of up to 31,247,383 shares of common stock by certain selling stockholders.
• The shares include 8,053,565 shares issuable upon conversion of Series C convertible preferred stock, 440,583 shares issuable upon exercise of warrants, 919,132 shares issuable upon conversion of promissory notes, and shares issuable under an equity line of credit with Seven Knots, LLC, up to a value of $23.8 million.
• The company will not receive any proceeds from the sale of shares by the selling stockholders, except for potential proceeds from the exercise of warrants (up to $0.2 million) and sales of ELOC Shares to Seven Knots (up to $23.8 million).
• Windtree intends to use any proceeds it receives for working capital and general corporate purposes.
• The company's common stock is traded on The Nasdaq Capital Market under the symbol WINT, with the last reported sale price on April 21, 2025, at $1.08 per share.
• Windtree has a history of operating losses and relies on securing additional capital to advance its development programs.
• The company is pursuing a new corporate strategy to become a revenue-generating biotech company through acquisitions of small companies with FDA-approved products.
• A 1-for-50 reverse stock split was effectuated on February 20, 2025, and the common stock began trading on a split-adjusted basis on February 21, 2025.
• As of December 31, 2024, Windtree had cash and cash equivalents of $1.8 million and current liabilities of $5.7 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing a new revenue-generating strategy and has potential funding sources, it also faces significant financial challenges, including operating losses and dependence on securing additional capital. The potential for dilution from future equity offerings and sales of shares by selling stockholders adds to the uncertainty.

Positives

• The equity line of credit with Seven Knots, LLC, provides a potential source of funding up to $23.8 million.
• The company is pursuing a new strategy to acquire revenue-generating biotech companies with FDA-approved products, which could improve its financial stability.
• The company has commercialization expertise in both large pharmaceutical and small biotech companies across multiple therapeutic areas, potentially enabling them to leverage synergies and optimize commercial performance across future subsidiaries.

Negatives

• The company has a history of operating losses and an accumulated deficit of $846.6 million as of December 31, 2024.
• The company's cash and cash equivalents were $1.8 million as of December 31, 2024, while current liabilities were $5.7 million.
• The company's ability to advance its development programs is dependent upon its ability to secure additional capital in both the near and long-term.

Risks

• The company's ability to continue as a going concern is dependent on securing additional capital.
• Sales of a substantial number of shares of common stock by the selling stockholders could cause the price of the common stock to decline.
• Future equity offerings may dilute existing stockholders' ownership.
• The company may use proceeds from sales of common stock in ways with which investors may not agree or in ways which may not yield a significant return.
• Seven Knots will pay less than the then-prevailing market price for our common stock, which could cause the price of our common stock to decline.
• Investors who buy shares of common stock from Seven Knots at different times will likely pay different prices.

Future Outlook

The company expects to continue incurring significant research and clinical development, regulatory, and other expenses as it develops its product candidates, seeks regulatory approvals, conducts clinical trials, and manufactures, markets, and sells any product candidates for which it may obtain regulatory approval.

Management Comments

• The Company will seek acquisition targets to achieve the Company's new corporate strategy.
• The Company's management team has commercialization expertise in both large pharmaceutical and small biotech companies across multiple therapeutic areas, potentially enabling them to leverage synergies and optimize commercial performance across future subsidiaries.
• The Company will seek to use equity to acquire subsidiaries.

Industry Context

Windtree's strategic shift towards acquiring revenue-generating biotech companies reflects a trend among smaller biotech firms to seek alternative business models to overcome commercialization challenges. This approach aims to leverage existing FDA-approved products to generate revenue while continuing to develop their own pipelines.

Comparison to Industry Standards

• Many small biotech companies struggle to maximize the commercialization potential of their FDA-approved products, creating an opportunity for companies like Windtree to acquire these assets.
• The acquisition of strategic subsidiaries with FDA-approved products is a common strategy used by parent companies to diversify their revenue streams and leverage synergies across multiple therapeutic areas.
• Companies like Ligand Pharmaceuticals and Royalty Pharma utilize similar business models, focusing on acquiring revenue-generating assets rather than solely relying on internal drug development.

Related Party Transactions

• The company has entered into an ELOC Purchase Agreement with Seven Knots, LLC, an equity line investor, whereby the company has the right, but not the obligation, to sell to Seven Knots, and Seven Knots is obligated to purchase from the company up to $23.8 million of newly issued shares of common stock.
• Seven Knots also purchased a Subject Note in an initial principal amount of $156,250.

Stakeholder Impact

• Shareholders may experience dilution as a result of future equity offerings and sales of shares by selling stockholders.
• Employees' job security may be affected by the company's financial performance and strategic decisions.
• Customers may benefit from the development and commercialization of new products.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• The company will continue to develop its product candidates.
• The company will seek regulatory clearances or approvals for its product candidates.
• The company will conduct clinical trials on its product candidates.
• The company will manufacture, market, and sell any product candidates for which it may obtain regulatory approval.
• The company will seek acquisition targets to achieve its new corporate strategy.
• An unblinded review of the data from the first 20 subjects in the SEISMiC C Study is planned to take place in Q3 2025.

Key Dates

Keywords

common stock, istaroxime, equity line of credit, preferred stock, warrants, biotech, cardiogenic shock, heart failure, SEISMiC Study, rostafuroxin, aPKCi inhibitor, Seven Knots, ELOC, financing, reverse stock split, Windtree Therapeutics